FOXP3 and melanoma: In a 2007 report, studying two groups of melanoma patients who either exhibited or did not exhibit local disease recurrence, it was shown that the percentage of CD4+ T cells which were CD25+FOXP3+ (as determined by dual IHC) was significantly elevated in the primary tumors of patients who had recurrent disease (92).